DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter
Open Access
- 23 April 2021
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 13 (1) , 1-18
Abstract
Background: Aberrant DNA methylation has been firmly established as a factor contributing to the pathogenesis of colorectal cancer (CRC) via its capacity to silence tumour suppressor genes. However, the methylation status of multiple tumour suppressor genes and their roles in promoting CRC metastasis are not well characterised. Methods: We explored the methylation and expression profiles of CPEB1 (the gene encoding cytoplasmic polyadenylation element-binding protein 1), a candidate CRC tumour suppressor gene, using The Cancer Genome Atlas (TCGA) database and validated these results in both CRC cell lines and cells from Han Chinese CRC patients (n = 104). The functional role of CPEB1 in CRC was examined in experiments performed in vitro and in vivo. A candidate transcription factor capable of regulating CPEB1 expression was predicted in silico and validated by luciferase reporter, DNA pull-down, and electrophoretic mobility shift assays. Results: Hypermethylation and decreased expression of CPEB1 in CRC tumour tissues were revealed by TCGA database. We also identified a significant inverse correlation (Pearson’s R = − 0.43, P < 0.001) between promoter methylation and CPEB1 expression. We validated these results in CRC samples and two CRC cell lines. We also demonstrated that up-regulation of CPEB1 resulted in significantly decreased tumour growth, migration, invasion, and tumorigenicity and promoted tumour cell apoptosis both in vitro and in vivo. We identified the transcription factors CCAAT enhancer-binding protein beta (CEBPB) and transcription factor CP2 (TFCP2) as critical regulators of CPEB1 expression. Hypermethylation of the CPEB1 promoter resulted in a simultaneous increase in the capacity for TFCP2 binding and a decreased likelihood of CEBPB binding, both of which led to diminished expression of CPEB1. Conclusions: Our results identified a novel tumour-suppressive role of CPEB1 in CRC and found that hypermethylation of the CPEB1 promoter may lead to diminished expression due to decreased chromatin accessibility and transcription factor binding. Collectively, these results suggest a potential role for CPEB1 in the diagnosis and treatment of CRC.Keywords
Funding Information
- National Natural Science Foundation of China (81974313)
This publication has 36 references indexed in Scilit:
- DNA methylation secures CD4+ and CD8+ T cell lineage bordersNature Immunology, 2015
- Regulation of DNA methylation dictates Cd4 expression during the development of helper and cytotoxic T cell lineagesNature Immunology, 2015
- Amelioration of Colorectal Cancer Using Negative Lipidoid Nanoparticles to Encapsulate siRNA Against APRIL by Enema Delivery ModePathology and Oncology Research, 2014
- CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in gliomaCell Death & Disease, 2013
- CPEB1 coordinates alternative 3′-UTR formation with translational regulationNature, 2013
- Cancer Epigenetics: From Mechanism to TherapyCell, 2012
- CPEB1 , a novel gene silenced in gastric cancer: a Drosophila approachGut, 2011
- CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translationNature, 2011
- Mitotic cell-cycle progression is regulated by CPEB1 and CPEB4-dependent translational controlNature Cell Biology, 2010
- CPEB is a specificity factor that mediates cytoplasmic polyadenylation during Xenopus oocyte maturationCell, 1994